Evaluating the Impacts of a Well-Being Mobile App in Mexico
NCT07109648, Not applicable, Active not recruiting, Raissa Fabregas
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Evaluating the Impacts of a Well-Being Mobile App in Mexico | ClinicalTrials.gov |
| NCT number | NCT07109648 | ClinicalTrials.gov |
| Status | Active not recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 4,000 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Raissa Fabregas | ClinicalTrials.gov |
| Conditions | Mental Health, Wellbeing | ClinicalTrials.gov |
| Interventions | Access to app | ClinicalTrials.gov |
| First posted | 2025-08-07 | ClinicalTrials.gov |
| Last updated | 2026-05-07 | ClinicalTrials.gov |
Registered outcomes 17
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Wellbeing | From enrollment to 3 and 8 weeks after | Measured using the World Health Organization-Five Well-Being Index (who-5). The raw score ranges from zero to 25, zero representing worst possible mental well-being and 25 representing best possible mental well-being. | ClinicalTrials.gov |
| Primary | Anxiety | From enrollment to 3 and 8 weeks after | Measured using General Anxiety Disorder-7 scale (GAD-7). This is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." GAD-7 total score for the seven items ranges from 0 to 21. The definitions are: 0-4: minimal anxiety (better outcome) 5-9: mild anxiety 10-14: moderate anxiety 15-21: severe anxiety (worse outcome) | ClinicalTrials.gov |
| Primary | Depression | From enrollment to 3 and 8 weeks after | Mesured using Personal Health Questionnaire Depression Scale (PHQ-8). This is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of "not at all," "several days," "more than half the days," and "nearly every day." PHQ-8 total score for the eight items ranges from 0 to 24. The definitions are: Less than 5: Minimal depression (better outcome) 5-9: Mild depression 10-14: Moderate depression 15-19: Moderately severe depression More or equal to 20: Severe depression (worse outcome) | ClinicalTrials.gov |
| Primary | Stress | From enrollment to 3 and 8 weeks after | Measured using Perceived Stress Scale 4 (PSS-4). The scores range from 0 to 16 where higher scores are correlated to more stress (worse outcome) | ClinicalTrials.gov |
| Secondary | Social media use - TikTok | At 3 and 8 weeks after enrollment | Number of days in the last seven days the participant used TikTok | ClinicalTrials.gov |
| Other | Ongoing affect | Weekly from rectuiment up to 12 weeks. | Measured through a purposely designed "emoji" survey, where the participants is asked how the participant is feeling. The options are very well, neutral, very bad. After it is constructed as a dummy variable that takes value of one if the participant answered "very well" or zero otherwise | ClinicalTrials.gov |
| Other | Sleep quantity | At 3 and 8 weeks after enrollment | hours slept the night before | ClinicalTrials.gov |
| Other | Sleep quality | At 3 and 8 weeks after enrollment | The number of times participants experienced sleep interruptions the night before | ClinicalTrials.gov |
| Other | Social media use - Facebook | At 3 and 8 weeks after enrollment | number of days in the last seven days the participant has used Facebook | ClinicalTrials.gov |
| Other | Psychotherapy | At 3 and 8 weeks after enrollment | If the participant visit recently a therapist | ClinicalTrials.gov |
| Other | Effort | At 3 and 8 weeks after enrollment | Performance on an incentive-compatible, real-effort task, where the participant needs to count the number of zeros in matrices of five columns and five rows where there are zeros and ones. The measure is the correct answers within one minute | ClinicalTrials.gov |
| Other | Emotional interference | At 3 and 8 weeks after enrollment | reaction time in the emotional Stroop task, specifically for matching colors of emotionally salient words. The emotional Stroop task is a variation of the Stroop effect that explores how emotional stimuli impact cognitive processing. Participants are presented with words in different colors and asked to name the ink color while ignoring the word's meaning. Longer reaction times for emotional words (e.g., "fear," "sadness") compared to neutral words (e.g., "table," "chair") indicate interference from the emotional content | ClinicalTrials.gov |
| Other | Healthful habits | At 3 and 8 weeks of enrollment | The index is calculated following Anderson (2008) and includes six standardized outcomes: the number of days in the last seven days the person exercised, went outside, did not miss work, did not raise her voice in anger, helped with homework, and had 10 minutes of self-time. | ClinicalTrials.gov |
| Other | Isolation | At 3 and 8 weeks of enrollment | Emotional and social isolation, measured by the Gierveld Loneliness Scale. It has a range of scores from 0 (least lonely, better outcome) to 6 (most lonely, worse outcome) | ClinicalTrials.gov |
| Other | Perceptions of efficacy | At 3 and 8 weeks after enrollment | measured using the Generalized Self-Efficacy Scale (GSE). The total score ranges between 10 and 40, with a higher score indicating more self-efficacy (better outcome). | ClinicalTrials.gov |
| Other | Social media use - X | At 3 and 8 weeks after enrollment | number of days in the last seven days the participant has used X | ClinicalTrials.gov |
| Other | Social media use - Instagram | At 3 and 8 weeks after enrollment | Number of days in the last seven days the participant used Instagram | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 3
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Emotional Stroop Task | Other outcome | ConductCognition |
| Real-Effort Slider Task | Other outcome | ConductCognition |
| Stroop Color-Word Test | Other outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)